Open access
Open access
Powered by Google Translator Translator

Single-arm phase 1–2 trial of AAVS3 gene therapy in patients with Hemophilia B.

21 Jul, 2022 | 13:23h | UTC

Phase 1–2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Novel gene therapy could reduce bleeding risk for hemophilia patients – University College London

Commentary: Hemophilia B Gene Therapy Produces Durable Response for 90% of Participants – AJMC

 

Commentary on Twitter

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.